FULCRUM THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
FULCRUM THERAPEUTICS, INC. (FULC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.00% for the 12-month period ending 2025-12-31, per its S-4 filed 2026-09-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.04%.
- FULCRUM THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.46%.
- FULCRUM THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -0.31%.
- FULCRUM THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was -0.79%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.00% S-4 · filed 2026-09-02 | |
| 2024-12-31 | -0.01% S-4 · filed 2026-09-02 | -0.90% 10-K · filed 2025-02-25 |
| 2023-12-31 | -0.04% 10-K · filed 2025-02-25 | -0.71% 10-K · filed 2024-02-27 |
| 2022-12-31 | -0.46% 10-K · filed 2024-02-27 | -0.69% 10-K · filed 2023-03-09 |
| 2021-12-31 | -0.31% 10-K/A · filed 2023-06-26 | |
| 2020-12-31 | -0.79% 10-K/A · filed 2023-06-26 | |
| 2019-12-31 | -0.67% 10-K/A · filed 2023-06-23 | |
| 2018-12-31 | -1.37% 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |